Related Experiment Video
Updated: Mar 17, 2026
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact
Brandon J Manley1, Abraham Ari Hakimi
1Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Purpose Of Review:
The daunting task of identifying key molecular drivers of renal cell carcinoma (RCC) has begun to reveal significant insights into tumor biology. This review provides an update on recent discoveries in this field and their possible clinical implications.
Recent Findings:
Molecular profiles within the classic RCC histologic subtypes present distinctive appreciation of tumor biology and also allow for exploitation of targeted treatment regimens for patients with metastatic disease. Prognostic signatures have demonstrated the ability to accurately predict many clinical outcomes.
Summary:
The molecular and genomic profiling of RCC subtypes has identified a unique and diverse spectrum of alterations. Utilization of these characteristics to improve our prognostic and therapeutic outcomes in the clinical realm remains in its infancy but is rapidly advancing.
Insights
Identifying key molecular drivers in renal cell carcinoma (RCC) reveals tumor biology insights. Recent discoveries offer potential targeted treatments and improved prognostic predictions for metastatic disease.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Renal cell carcinoma (RCC) presents complex tumor biology.
- Identifying molecular drivers is crucial for understanding RCC.
- Recent advancements offer new therapeutic avenues.
Purpose of the Study:
- To review recent discoveries in molecular drivers of RCC.
- To discuss the clinical implications of these findings.
- To provide an update on targeted treatment strategies.
Main Methods:
- Review of recent scientific literature.
- Analysis of molecular and genomic profiling data in RCC.
- Evaluation of prognostic signatures.
Main Results:
- Distinct molecular profiles exist within RCC histologic subtypes.
- Targeted treatment regimens can be exploited for metastatic RCC.
- Prognostic signatures accurately predict clinical outcomes.
Conclusions:
- Molecular profiling of RCC subtypes reveals a diverse spectrum of alterations.
- Clinical application of these findings for prognosis and therapy is advancing rapidly.
- Further research is needed to fully utilize these molecular characteristics.
